10139-91-0

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-aminophenyl)-propionitrile is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its unique structure allows for the formylation and condensation of glycinate, which is crucial in the synthesis of certain drugs.
Used in Enzyme Inhibition:
In the field of biochemistry and pharmacology, AAFP is utilized in the preparation of inhibitors of purine nucleoside phosphorylase (PNP). PNP inhibitors have potential applications in the treatment of autoimmune diseases, cancer, and other conditions where the modulation of purine metabolism is desired.
By following the structure provided in the example, the final result for 3-(4-aminophenyl)-propionitrile is as follows:

Uses

Used in Pharmaceutical Industry:
3-(4-aminophenyl)-propionitrile is used as a synthetic intermediate for the development of various pharmaceutical compounds, enabling the formylation and condensation of glycinate in drug synthesis.
Used in Enzyme Inhibition:
3-(4-aminophenyl)-propionitrile is used in the preparation of inhibitors of purine nucleoside phosphorylase (PNP) for potential applications in treating autoimmune diseases, cancer, and other conditions related to purine metabolism.

Upstream product

• 53563-09-0 3-(4-nitrophenyl)propanenitrile 
• 27892-88-2 p-nitrocinnamonitrile 
• 555-16-8 4-nitrobenzaldehdye 
• 105-56-6 ethyl 2-cyanoacetate 
• 16642-79-8 3-(4-nitrophenyl)propionic acid 
• 98953-18-5 3-(4-nitrophenyl)propionamide 
• 645-59-0 dihydrocinnamonitrile 
• 77120-14-0 (E)-3-(4-aminophenyl)acrylonitrile 

Downstream Products

• 146385-65-1 4-iodobenzenepropanenitrile 
• 17362-17-3 3-(p-hydroxyphenyl)propiononitrile 
• 854272-94-9 3-(4-amino-3-chloro-phenyl)propionitrile 
• 60-82-2 3-(4-Hydroxy-phenyl)-1-(2,4,6-trihydroxy-phenyl)-propan-1-on 
• 146386-08-5 3-(3-Benzoyl-thioureido)-4-(4-iodo-benzyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 146386-22-3 3-(3-Benzoyl-2-methyl-isothioureido)-4-(4-iodo-benzyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 1026098-46-3 3-Amino-4-(4-iodo-benzyl)-pyrrole-1,2-dicarboxylic acid 1-ethyl ester 2-methyl ester 
• 146385-94-6 3-Amino-4-(4-iodo-benzyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 1026156-80-8 2-Formyl-3-(4-iodo-phenyl)-propionitrile 

Relevant academic research and scientific papers

Synthesis of Nitriles from Aldehydes with Elongation of the Molecule with Two Carbon Atoms

A new protocol for the synthesis of nitriles from carbonyl compounds with elongation of the molecule with two carbon atoms was developed. It involves a reaction of ethyl cyanoacetate with different aldehydes in the presence of iron pentacarbonyl as a redu

(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

HIV INHIBITING 1,2,4-TRIAZIN-6-ONE DERIVATIVES

The present invention relates to HIV replication inhibitors of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein ring A and ring B represent phenyl, pyridyl, pyridaz

1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The invention relates to imidazoquinolines of formula (I) for use in the treatment of protein kinase dependent diseases; pharmaceutical preparations comprinsing an imidazoquinoline, especially for the treatment of a pretein kinase dependent disease; novel imidazoquinolines; and a process for the preparation of the novel imidazoquinilines.

1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(Arylmethyl) derivatives of 9-deazaguanine

Purine nucleoside phosphorylase (PNP, EC 2.4.2.1) is a salvage enzyme important to the T-cell-mediated part of the immune system and as such is an important therapeutic target. This paper describes the design, synthesis, and enzymatic evaluation of potent, competitive inhibitors of PNP. Potential inhibitors were designed using the three-dimensional structure of the enzyme in an iterative process that involved interactive computer graphics to model the native enzyme and complexes of it with the inhibitors, Monte Carlo-based conformational searching, and energy minimization. Studies of the enzyme/inhibitor complexes were used to determine priorities of the synthetic efforts. The resulting compounds were then evaluated by determination of their IC50 values and by X-ray diffraction analysis using difference Fourier maps. In this manner, we have developed a series of 9-(arylmethyl)- 9-deazapurines (2-amino-7-(arylmethyl)-4H-pyrrolo[3,2-d]-pyrimidin-4-ones) that are potent, membrane-permeable inhibitors of the enzyme. The IC50 values of these compounds range from 17 to 270 nM (in 1 mM phosphate), with 9-(3,4-dichlorobenzyl)-9-deazaguanine being the most potent inhibitor. X-ray analysis explained the role of the aryl groups and revealed the rearrangement of hydrogen bonds in the binding of the 9-deazaguanines in the active site of PNP relative to the binding of the 8-aminoguanines that results in more potent inhibition of the enzyme.